Sanofi to acquire immuno-oncology company Synthorx for $2.5B
The San Diego-based biotech is developing IL-2 therapeutics for cancers as well as autoimmune disorders. Its lead candidate, THOR-707, is in a Phase I/II study in solid tumors.
Startup developing semi-synthetic protein therapies raises $63M to tame IL-2
Interleukin-2 has been plagued by low responses and scary side effects but Synthorx is adding synthetic amino acids and a polymer to the treatment in an effort to make it a more effective cancer therapy
The Mechanics of a More Connected Healthcare Ecosystem [Video]
Arbiter’s Anjali Jameson on hospital and payer alignment.
Synthorx receives $10M to pivot toward treatments
The money will be used to develop products by leveraging its synthetic amino acid platform as well as to hire chief business and scientific officers.